Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,541
  • Shares Outstanding, K 80,421
  • Annual Sales, $ 53,400 K
  • Annual Income, $ 2,930 K
  • EBIT $ 6 M
  • EBITDA $ 8 M
  • 60-Month Beta -0.25
  • Price/Sales 2.73
  • Price/Cash Flow 31.46
  • Price/Book 2.73

Options Overview Details

View History
  • Implied Volatility 112.91% (-1.14%)
  • Historical Volatility 50.27%
  • IV Percentile 40%
  • IV Rank 4.42%
  • IV High 1,386.23% on 07/10/25
  • IV Low 54.04% on 08/19/25
  • Expected Move (DTE 28) 0.0425 (2.36%)
  • Put/Call Vol Ratio 4.17
  • Today's Volume 62
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 4,881
  • Open Int (30-Day) 5,589
  • Expected Range 1.7575 to 1.8425

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.04
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate 0.03
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6500 +9.09%
on 12/03/25
1.8800 -4.26%
on 11/20/25
-0.0800 (-4.26%)
since 11/18/25
3-Month
1.6000 +12.50%
on 10/17/25
2.6550 -32.20%
on 10/07/25
-0.0600 (-3.23%)
since 09/18/25
52-Week
1.3200 +36.36%
on 06/23/25
3.1000 -41.94%
on 05/01/25
+0.0900 (+5.26%)
since 12/18/24

Most Recent Stories

More News
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator ® platform to jointly develop pharmaceutical candidates for rare renal indications...

PLX : 1.8000 (+2.27%)
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EST

PBD : 15.95 (+1.01%)
PLX : 1.8000 (+2.27%)
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Company to host conference call and webcast at 8:00 a.m. EST

PLX : 1.8000 (+2.27%)
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the...

PLX : 1.8000 (+2.27%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors...

PLX : 1.8000 (+2.27%)
Levi & Korsinsky Launches Fraud Investigation on Behalf of Protalix BioTherapeutics, Inc. (PLX) Shareholders

New York, New York--(Newsfile Corp. - October 27, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Protalix BioTherapeutics, Inc. ("Protalix BioTherapeutics, Inc.")...

PLX : 1.8000 (+2.27%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors...

PLX : 1.8000 (+2.27%)
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CARMIEL, Israel , Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.8000 (+2.27%)
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT

PBD : 15.95 (+1.01%)
PLX : 1.8000 (+2.27%)
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Company to host conference call and webcast at 8:30 a.m. EDT

PBD : 15.95 (+1.01%)
PLX : 1.8000 (+2.27%)

Business Summary

Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.

See More

Key Turning Points

3rd Resistance Point 1.8833
2nd Resistance Point 1.8467
1st Resistance Point 1.8233
Last Price 1.8000
1st Support Level 1.7633
2nd Support Level 1.7267
3rd Support Level 1.7033

See More

52-Week High 3.1000
Fibonacci 61.8% 2.4200
Fibonacci 50% 2.2100
Fibonacci 38.2% 2.0000
Last Price 1.8000
52-Week Low 1.3200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar